# Healthcare AI Acquisition Corp. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Healthcare AI Acquisition Corp.). ## Overview Healthcare AI Acquisition Corp. is a special purpose acquisition company (SPAC) formed to complete a merger, share exchange, asset acquisition, or similar business combination with an operating business. It has not yet generated operating revenue and currently earns only interest income on trust-account investments while it searches for a target, with a stated focus implied by its name on healthcare and AI-related opportunities. ## Products & services • SPAC structure for acquiring an operating business • Initial business combination execution • Trust-account capital deployment • Public-market listing vehicle for a target company - **SPAC formation and capital pool** (100%) — Public-company shell structure that holds IPO proceeds in trust until a business combination is completed or the company liquidates. - **Business combination execution** (0%) — Transaction structuring, negotiation, and closing of a merger or similar acquisition with a target operating business. - **Administrative and sponsor support** (0%) — Minimal corporate administration and sponsor-provided services during the search period. - SPAC vehicle to merge with an operating company - Initial business combination sourcing and execution - Trust-account capital held for a future transaction - Public listing path for a private target - Administrative support during the search period ## Customers The company does not sell products or services to end customers in the normal operating sense. Its economic counterparties are investors, sponsors, directors, and a future target business that may become the operating company after a business combination. Until a transaction closes, the company’s value proposition is access to public capital and a Nasdaq-listed acquisition vehicle. - **Public shareholders** (primary) — Buy the listed shares and warrants for exposure to a future business combination and potential post-merger upside. - **Sponsor and insiders** (primary) — Provide capital, administrative support, and transaction oversight to complete a business combination. - **Target operating company** (primary) — Would combine with the SPAC to access public markets and capital more quickly than a traditional IPO. - Public shareholders seeking SPAC exposure and potential deal upside - Sponsor and directors supporting the acquisition process - A future target company seeking a public listing route - Investors in trust-account securities awaiting a transaction - Potential merger counterparties in healthcare/AI-adjacent sectors ## Geography The company is domiciled in the United States and its securities were listed on Nasdaq, but it has no operating revenue or operating footprint yet. Geography matters mainly through the location of potential targets and regulatory review, including possible CFIUS scrutiny if the eventual transaction involves foreign ownership or sensitive U.S. businesses. The reports also note that certain directors and the business combination counterparty have non-U.S. ties, which can affect deal execution risk. - United States domicile and Nasdaq listing - No operating revenue or manufacturing footprint yet - Potential target search may extend beyond the U.S. - Foreign ownership and CFIUS review can affect deal closing - Singapore/Cayman-linked counterparty increases cross-border complexity ## Strategy The core strategy is to complete an initial business combination before the termination date, or else liquidate. Management is also focused on preserving liquidity through sponsor support or working-capital loans while navigating regulatory, listing, and foreign-investment constraints that could narrow the target pool. - **Complete an initial business combination** (short-term) — The SPAC has no operating business until a transaction closes, so execution is existential. - **Maintain liquidity and transaction optionality** (short-term) — The company needs enough cash to fund search, diligence, and closing costs. - **Navigate regulatory and listing constraints** (short-term) — CFIUS, SEC rules, and Nasdaq compliance can delay or block a deal. - Close a business combination before the termination date - Preserve cash through sponsor and working-capital support - Manage Nasdaq, SEC, and CFIUS-related transaction risk - Target a healthcare/AI-related operating business - Avoid liquidation by securing an acceptable merger candidate ## Risks The company faces classic SPAC risks: failure to complete a business combination, forced liquidation, and the possibility that warrants expire worthless. It also faces regulatory and market-structure risks from Nasdaq delisting, penny-stock treatment, and potential Investment Company Act issues, while cross-border ownership and CFIUS review could reduce the target pool or delay closing. - **Failure to complete a business combination before the termination date** [critical] — The company has no operating business and must liquidate if it cannot close a transaction in time. - **Investment Company Act classification** [critical] — If deemed an unregistered investment company, the SPAC may be forced to abandon the deal process and liquidate. - **Nasdaq delisting and penny-stock designation** [high] — Trading suspension and delisting reduce liquidity and can impair the ability to complete a transaction. - **CFIUS and foreign ownership review** [high] — Cross-border directors and counterparties may trigger review, delay, or conditions on a deal. - No deal by termination date would trigger liquidation - Investment Company Act risk could force liquidation - Nasdaq delisting and penny-stock status hurt liquidity - CFIUS or foreign-ownership issues may block a target - Working capital may be insufficient without sponsor support ## Accounting The main accounting issue is that the company has no operating revenue, so results are driven by trust-account interest income, operating costs, and fair-value changes in warrant liabilities. Investors should watch redemption accounting, temporary equity treatment of offering costs, and the valuation of warrants, because these items can swing reported income even when the underlying business has not changed. - **Fair value of warrant liability** — Reported net income can swing materially quarter to quarter - **Trust-account interest income** — Declines as redemptions reduce trust balance - **Offering costs and temporary equity** — Impacts balance sheet classification and early-period results - **Going-concern assessment** — Material disclosure and liquidation risk - Trust-account interest income is the main recurring income source - Warrant liability fair value changes drive earnings volatility - Offering costs were charged to temporary equity - Redemptions reduce trust balance and future interest income - Going-concern assessment depends on deal completion timing --- *Last updated: 2026-04-28T20:14:30.419068+00:00*